Abstract C056: Risk of Immune-related adverse events with immune checkpoint inhibitors in locally advanced nasopharyngeal carcinoma: A meta-analysis of randomized controlled trials

医学 内科学 肿瘤科 不利影响 随机对照试验 佐剂 吉西他滨 鼻咽癌 危险系数 置信区间 临床试验 顺铂 入射(几何) 癌症 临床研究阶段 相对风险 随机化 无容量 辅助治疗
作者
Ramaditya Srinivasmurthy,Rishi Kumar Nanda,Daniel Thomas Jones,Taimur Khalid,Jason Ta,Kenny Do,Riccesha Hattin,Abbas Hussain,Yin Mon Myat,Sisi Tian,Jo‐Lawrence Bigcas,Kyaw Zin Thein
出处
期刊:Molecular Cancer Therapeutics [American Association for Cancer Research]
卷期号:24 (10_Supplement): C056-C056
标识
DOI:10.1158/1535-7163.targ-25-c056
摘要

Abstract Background: Nasopharyngeal carcinoma (NPC) is a malignant epithelial tumor of the nasopharyngeal mucosa, with a high prevalence in East and Southeast Asia. The standard treatment for locally advanced (LA) NPC is chemoradiation therapy (CRT), with regimens typically consisting of cisplatin and 5-fluorouracil or gemcitabine. The integration of immune checkpoint inhibitors (ICIs) into treatment regimens has shown improved survival benefits, however, it raises concerns for treatment-related adverse events (AEs). This study aims to evaluate the risk of immune-related AEs (irAEs) in patients with LA NPC treated with ICIs. Methods: A comprehensive literature search was conducted using MEDLINE and EMBASE databases from inception through June 1st 2025. Randomized controlled trials (RCTs) utilizing ICIs in LA NPC reporting irAEs were included. Mantel-Haenszel method was used to calculate the estimated pooled risk ratio (RR) with 95% confidence interval (CI). Heterogeneity was assessed using Cochran's Q-statistic. A fixed effects model was employed. Results: This meta-analysis included 1,016 patients from two phase III trials (CONTINUUM: n=508; DIPPER: n=278) and one phase II trial (Liu Se et al., 2024: n=230), all evaluating immune checkpoint inhibitors (ICIs) in locoregionally advanced nasopharyngeal carcinoma. In CONTINUUM, patients received induction gemcitabine and cisplatin followed by chemoradiotherapy, with or without sintilimab during induction, concurrent, and adjuvant phases. DIPPER randomized patients post-chemoradiotherapy to adjuvant camrelizumab or observation. The phase II trial assessed neoadjuvant and adjuvant toripalimab vs placebo, with a 2:1 randomization before and after chemoradiotherapy. The incidence of the following irAEs was significantly higher in the ICI arm compared to the control arm: any-grade irAEs 71.15% vs 2.26% (RR 22.92; CI: 13.99–37.57, p<0.00001), high-grade irAEs 7.80% vs 0% (RR 23.62; CI: 4.83–115.49, p<0.0001), grade 1 or 2 hypothyroidism 29.04% vs 9.48% (RR 3.04; CI: 2.24–4.11, p<0.00001), any-grade rash 17.34% vs 0.82% (RR 15.57; CI: 6.55–36.98, p<0.00001), high-grade rash 3.31% vs 0% (RR 13.28; CI: 1.86–94.98, p=0.010), any-grade pruritus 20.27% vs 1.44% (RR 12.29 CI: 5.96–25.34, p<0.00001), and any-grade allergic reaction 2.34% vs 0% (RR 7.66; CI: 1.48–39.71, p=0.02). In contrast, the incidence of high-grade pruritus and allergic reaction was not statistically significantly different between the two treatment groups. Conclusion: This study revealed that patients with LA NPC treated with ICIs in addition to CRT have a higher risk of developing irAEs in general compared to those treated with standard therapy. Early detection of these AEs and providing the appropriate supportive care is essential to optimize the outcomes and maintain patients’ quality of life and compliance. Citation Format: Ramaditya Srinivasmurthy, Rishi K. Nanda, Daniel T. Jones, Taimur Khalid, Jason Ta, Kenny Do, Riccesha Hattin, Abbas Hussain, Yin M. Myat, Sisi Tian, Jo-Lawrence Bigcas, Kyaw Z. Thein. Risk of Immune-related adverse events with immune checkpoint inhibitors in locally advanced nasopharyngeal carcinoma: A meta-analysis of randomized controlled trials [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; 2025 Oct 22-26; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2025;24(10 Suppl):Abstract nr C056.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
lily完成签到,获得积分10
刚刚
壁虎君完成签到,获得积分10
3秒前
3秒前
王达发布了新的文献求助10
4秒前
4秒前
heart完成签到,获得积分10
4秒前
biancaliu发布了新的文献求助10
4秒前
4秒前
随风逐梦完成签到,获得积分10
5秒前
科研通AI2S的应助被lmg采纳,获得10
5秒前
害怕的穆发布了新的文献求助10
6秒前
obtio完成签到,获得积分20
6秒前
xu1227发布了新的文献求助10
8秒前
兜兜想哒哒完成签到,获得积分10
8秒前
Tang完成签到,获得积分10
8秒前
9秒前
wang完成签到,获得积分10
9秒前
t250完成签到,获得积分10
9秒前
蓝海鸥发布了新的文献求助10
9秒前
10秒前
10秒前
12秒前
zz发布了新的文献求助10
13秒前
传奇3的应助被CTx采纳,获得10
14秒前
mldzyx发布了新的文献求助30
16秒前
害怕的穆完成签到,获得积分20
16秒前
lmg发布了新的文献求助10
16秒前
17秒前
abc发布了新的文献求助10
17秒前
OK的应助被KK采纳,获得80
17秒前
小陈陈发布了新的文献求助10
17秒前
19秒前
19秒前
zz完成签到,获得积分20
19秒前
19秒前
20秒前
打打的应助被a1313采纳,获得10
20秒前
CodeCraft的应助被ljj采纳,获得10
21秒前
熙攘发布了新的文献求助10
22秒前
激昂的鼠标完成签到,获得积分10
22秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183204
求助须知:如何正确求助?哪些是违规求助? 9572482
关于积分的说明 21825940
捐赠科研通 7780074
什么是DOI,文献DOI怎么找? 3433945
关于科研通互助平台的介绍 2558060
邀请新用户注册赠送积分活动 2480166